Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (3288)	2/20/2013 12:37:07 PM
From: richardred	Respond to of 7242

OMPI's new co marketing partner is Suneva Medical which is owned by HealthCare Royalty Partners. IMO a good acquisition for them if OMPI gets pushed. L'Oreal is still looking also. >snip L'Oreal ( OREP.PA), the world's biggest cosmetics group, said it was still open to making an acquisition, a day after unveiling plans to return 500 million euros ($669 million) to shareholders. Chief Executive Jean-Paul Agon said on Tuesday the French company had the "means and the guts" to do a takeover deal, helped by a 1.58-billion-euro cash pile at the end of 2012. reuters.com HealthCare Royalty Partners Commits Over $300 Million in New Investments in December and Over $425 Million in 2012TAMFORD, Conn., Jan. 3, 2013 /PRNewswire/ -- HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced that it committed over $300 million in December 2012 across five investments. Total capital committed by the HC Royalty team in 2012 exceeded $425 million. "2012 proved to be another robust year for deal activity in the royalty market. Our team evaluated several hundred investment opportunities and committed a significant amount of capital across eight investments. We believe the strength of this market is further validation that companies need access to a greater pool of capital to bring critical products to patients and move their pipelines forward," commented Todd Davis, Founding Managing Director at HC Royalty. He continued, "Our firm has been a significant financial resource for commercial stage and near commercial stage companies, as we offer a broad and flexible investment platform that delivers non-dilutive forms of capital." Select 2012 product investments include: LYRICA®: HC Royalty purchased a royalty interest in LYRICA® from an inventor. LYRICA® is one of Pfizer's premier drugs for the treatment of neuropathic pain with trailing twelve month sales exceeding $3.5 billion worldwide. The firm believes this is one of the largest stand-alone inventor monetizations consummated. Meningitec™, HibTITER®, NU100 and several other products: An $80 million structured financing was completed with privately-held Nuron Biotech. The financing included a $30 million equity investment and a $50 million Synthetic Royalty® agreement tied to future sales of Meningitec™, HibTITER® and the company's other products, including NU100. The capital is being used to support the commercialization and expansion of Meningitec™ (recently acquired from Pfizer), an established commercial vaccine for the prevention of invasive disease caused by Neisseria meningitidis serogroup C. It is also being used to fund the clinical development of the company's novel biologics and vaccines for infectious and neurodegenerative diseases. The financing is a structured deal that offers less dilutive growth capital for an emerging biopharmaceutical company. PROCYSBI™: A $50 million loan agreement was completed with Raptor Pharmaceuticals ( RPTP) to help fund the commercialization of PROCYSBI™, the branded name of RP103 for the potential treatment of nephropathic cystinosis, and to advance the company's development programs. The loan which matures on December 31, 2019, bears interest at an annual fixed rate of 10.75% and a Synthetic Royalty® variable rate, tiered down, based on a percentage of future PROCYSBI sales. This financing represents another form of non-dilutive growth capital for a company on the verge of approval and launch of an important therapeutic product to treat an orphan indication. Eligard®: HC Royalty acquired a royalty interest in Eligard® European sales from Medigene AG for $18 million. Eligard is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer that is currently marketed by AstellasPharma Europe Ltd. This non-dilutive financing enabled Medigene to fund its pipeline including the company's lead drug candidate, Endotag for the treatment of pancreatic and breast cancer. About HealthCare Royalty Partners HealthCare Royalty Partners is a global healthcare investment firm focused on providing financing solutions to healthcare companies and royalty owners with interests in approved pharmaceutical and medical device products. The firm's senior investment team has participated in 45 royalty financings valued at over $2 billion over the past decade. For more information, visit www.healthcareroyalty.com/.

To: richardred who wrote (3288)	3/14/2013 12:09:33 PM
From: richardred	Read Replies (1) \| Respond to of 7242

RE:OMPI Sink or swim tomorrow. Earnings after the close. P.S. With past AVP rumors on OMPI- Does general corporate purposes mean spending some money on synergistic acquisitions? Or will Sherri just keep repairing the the boat from inside? Theoretically speaking, any OMPI would most likely not be accretive to earnings. Plus the last acquisition (Silpada)was a disaster. L'Oreal still looking for bolt ons. reuters.com OMPI Skin care products are expensive. L’Oreal adds direct sale of luxury range in Romania, sees growth potential for expensive cosmetics. romania-insider.com Avon closes $1.5B note offering, will repay debt Avon Products closes on $1.5 billion notes offering; plans to repay $1.9 billion of debt NEW YORK (AP) -- Avon has completed a public offering of $1.5 billion senior unsecured notes and entered into a $1 billion four-year unsecured revolving credit facility. The refinancing activities have improved the company's balance sheet and increased its financial flexibility, said Kimberly Ross, who is executive vice president and chief financial officer. Ross said the refinancing is "critical to our ability to successfully execute Avon's turnaround." Its stock gained 20 cents to $20.38 in midday trading. Avon Products Inc. has embarked on a turnaround plan after suffering through declining sales, a bribery investigation and other problems. It hired new CEO Sheri McCoy last April and has begun to slash costs, hoping to save $400 million in three years, cut its dividend, laid off workers and exited some less profitable markets like Vietnam and South Korea. The beauty products company had issued the notes earlier this month and at that time said that it would use proceeds to refinance debt and for general corporate purposes. On Thursday Avon said that the net proceeds from the notes totaled $1.48 billion, after transaction costs. The New York company said that it plans to repay $1.9 billion of debt. Avon said that the $1 billion revolving credit facility replaces a previous $1 billion revolving credit facility.

To: richardred who wrote (3288)	3/20/2013 8:44:44 AM
From: richardred	2 Recommendations Read Replies (2) \| Respond to of 7242

Bulls-eye -today in OMPI- first successful takeout pick this year.:+ ) Valeant to buy Obagi Medical for about $344 mln Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio. The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price. Obagi's board has unanimously approved the deal, Valeant said in a statement. reuters.com